Skip to main content

Table 2 Patient Characteristics of the COEUR cohort

From: Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

Histotypes   HGSC EC LGSC CCC MC Total
Number of samples per histotypes 1246 296 102 259 88 1991
Age diagnosis (years) Mean 62 58 53 56 53 60
Age end of follow-up (years) Mean 66 63 59 61 58 64
Follow-up time (months) Mean 47 64 60 58 52 51
Min-Max 0–211 0–268 0–270 0–247 1–228 0–270
Total N 1240 294 102 258 87 1983
Stage 1 70(6%) 145(54%) 13(14%) 127(52%) 61(74%) 416
2 137(12%) 74(28%) 7(7%) 54(22%) 11(13%) 283
3 835(72%) 45(17%) 67(72%) 58(23%) 8(9%) 1013
4 123(11%) 5(2%) 6(6%) 7(3%) 3(3%) 144
Total N 1165 269 93 246 83 1856
Residual Disease none 207(28%) 120(75%) 16(22%) 93(68%) 36(81%) 472(36%)  
< 1 cm 231(31%) 29(18%) 21(32%) 26(19%) 4(10%) 310(24%)  
suboptimal 387(47%) 11(7%) 27(41%) 17(12%) 4(10%) 110(8%)  
Total 824 160 64 136 44 1311
BRCA1 and BRCA2 mutation status Mutation status known but not identified (%) 1(< 1%)) 0 1(3%) 0 0 2(< 1%)
BRCA1 Carriers (%) 68(14%) 0 2(6%) 0 0 70(12%)
double BRCA1/BRCA2 carrier (%) 4(< 1%) 0 0 0 0 4(< 1%)
BRCA2 carriers (%) 35(7%) 0 1(3%) 0 0 36(6%)
Non carriers (%) 370(76%) 44(100%) 31(89%) 25(100%) 6(100%) 476(80%)
Carriers of variants of unknown significance 10(2%) 0 0 0 0 10(< 2%)
Total BRCA mutation carrier 108 0 4 0 0 112
Survival rate Alive 386(32%) 227(83%) 45(45%) 148(59%) 63(73%) 869(45%)
Deceased 830 47 56 107 23 1063
Total 1216 274 101 255 86 1932
5-years survival rate Alive 353(34%) 138(80%) 46(54%) 118(57%) 34(65%) 689(44%)
Deceased 678 35 39 89 18 859
Total 1031 173 85 207 52 1548
Response to treatmenta sensitive 421(68%) 27(73%) 29(60%) 16(44%) 4(57%) 497(66%)
resistant 201 10 19 20 3 253
Total 622 37 48 36 7 750
Chemotherapy before first progression none 22(2%) 35(14%) 8(67%) 15(6%) 37(53%) 117(7%)
carbo+taxol 955(81%) 184(74%) 66(67%) 195(82%) 31(40%) 1431(78%)
cispl+taxol 71(62%) 8(3%) 10(11%) 6(3%) 0 95(5%)
platinum 63(5%) 14(6%) 7(7%) 13(5%) 3(4%) 100(6%)
platinum+other 38(3%) 6(2%) 5(6%) 6(2.5%) 1(1%) 56(3%)
taxol 3(< 1%) 0% 0 0 0 3(< 1%)
other 17(1%) (< 1%) 0 3(1%) 1(< 1%) 22(1%)
Total 1169 248 96 238 73 1824
Long term survivors (>  10 years) yes 73(8%) 38(45%) 10(16%) 23(18%) 7(23%) 151(13%)
no 818 47 54 102 23 1044
Total 891 85 64 125 30 1195
  1. Borderline ovarian tumor cases were excluded
  2. N number of case, carbo carboplatinum, cispl cisplatinum, BOT Borderline Ovarian Tumor, HGSC High-Grade Serous Carcinoma
  3. apatients with platinum-based treatment